ADC Therapeutics S.A. (ADCT)
NYSE · Healthcare
ADC Therapeutics S.A. Operating Income 2022–2025
ADC Therapeutics S.A. annual/quarterly operating income history and growth rate from 2022 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- ADC Therapeutics S.A. operating income for the quarter ending March 31, 2026 was -25.2 M, a 11.31% decrease year-over-year.
- ADC Therapeutics S.A. operating income for the twelve months ending March 31, 2026 was -128.8 M, a 4.12% decrease year-over-year.
- ADC Therapeutics S.A. annual operating income for 2025 was -121.5 M, a 7.01% decrease from 2024.
- ADC Therapeutics S.A. annual operating income for 2024 was -130.7 M, a 21.29% decrease from 2023.
- ADC Therapeutics S.A. annual operating income for 2023 was -166.0 M, a 34.57% increase from 2022.
- ADC Therapeutics S.A. annual operating income for 2022 was -123.3 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
ADC Therapeutics S.A. Operating Income — FAQ
ADC Therapeutics S.A. (ADCT) operating income over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
What is ADC Therapeutics S.A.'s operating income?
ADC Therapeutics S.A. (ADCT) reported operating income of -$121M for fiscal 2025.
Where can I see ADCT's operating income history?
The chart and table above show ADC Therapeutics S.A.'s operating income by year and by quarter, including the growth rate.